Cargando…

Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009

The pathology of rheumatoid arthritis includes synoviocyte proliferation and inflammatory mediator expression, which may result from dysregulated epigenetic control by histone deacetylase (HDAC). Thus, HDAC inhibitors may be useful for treating inflammatory disease. This was a preclinical study of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsieh, I-N, Liou, J-P, Lee, H-Y, Lai, M-J, Li, Y-H, Yang, C-R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424110/ https://www.ncbi.nlm.nih.gov/pubmed/24722291 http://dx.doi.org/10.1038/cddis.2014.133

Ejemplares similares

Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma
por: Chen, Mei-Chuan, et al.
Publicado: (2015)

Optimization and Development of Selective Histone Deacetylase Inhibitor (MPT0B291)-Loaded Albumin Nanoparticles for Anticancer Therapy
por: Putri, Athika Darumas, et al.
Publicado: (2021)

Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo
por: Huang, Han-Lin, et al.
Publicado: (2012)

Correction: Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo
por: Huang, Han-Li, et al.
Publicado: (2012)

Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo
por: Huang, Han-Li, et al.
Publicado: (2014)

A Potent Histone Deacetylase Inhibitor MPT0E028 Mitigates Emphysema Severity via Components of the Hippo Signaling Pathway in an Emphysematous Mouse Model
por: Yeh, Lu-Yang, et al.
Publicado: (2022)

Histone deacetylase inhibitor MPT0B291 suppresses Glioma Growth in vitro and in vivo partially through acetylation of p53
por: Buyandelger, Batsaikhan, et al.
Publicado: (2020)

The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model
por: Fan, Sheng-Jun, et al.
Publicado: (2018)

Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis
por: Huang, Yen-Chia, et al.
Publicado: (2015)

Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells
por: Tsai, Feng-Lung, et al.
Publicado: (2023)

Targeting Autophagy by MPT0L145, a Highly Potent PIK3C3 Inhibitor, Provides Synergistic Interaction to Targeted or Chemotherapeutic Agents in Cancer Cells
por: Chen, Chun-Han, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of (S)-Ketoprofen Co-Administered with Caffeine: A Preclinical Study in Arthritic Rats
por: Medina-López, Raúl, et al.
Publicado: (2018)

Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib
por: Tsai, A-C, et al.
Publicado: (2014)

Combining an Autophagy Inhibitor, MPT0L145, with Abemaciclib Is a New Therapeutic Strategy in GBM Treatment
por: Hsieh, Tsung-Han, et al.
Publicado: (2021)

Discovery of potent histone deacetylase inhibitors with modified phenanthridine caps
por: Fan, Wenli, et al.
Publicado: (2021)

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells
por: Chen, M-C, et al.
Publicado: (2013)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Thioester derivatives of the natural product psammaplin A as potent histone deacetylase inhibitors
por: Baud, Matthias G J, et al.
Publicado: (2013)

Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer
por: Takai, Noriyuki, et al.
Publicado: (2010)

Discovery of indole-3-butyric acid derivatives as potent histone deacetylase inhibitors
por: Chen, Yiming, et al.
Publicado: (2021)

A novel action mechanism for MPT0G013, a derivative of arylsulfonamide, inhibits tumor angiogenesis through up-regulation of TIMP3 expression
por: Wang, Chih-Ya, et al.
Publicado: (2014)

The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects
por: West, Alison C., et al.
Publicado: (2012)

KMg(0.09)Fe(1.91)(PO(4))(2)
por: Yatskin, Michael M., et al.
Publicado: (2012)

Bromfenac 0.09% for the Treatment of Macular Edema Secondary to Noninfectious Uveitis
por: Saade, Joanna S., et al.
Publicado: (2021)

Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms
por: Mehndiratta, Samir, et al.
Publicado: (2020)

HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models
por: Ke, Hang, et al.
Publicado: (2023)

MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells
por: Huang, Fang-I, et al.
Publicado: (2019)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Histone deacetylase signaling in cardioprotection
por: Lehmann, Lorenz H., et al.
Publicado: (2013)

Inhibitors of human histone deacetylase with potent activity against the African trypanosome Trypanosoma brucei
por: Kelly, John M., et al.
Publicado: (2012)

Synthetic Routes and Biological Evaluation of Largazole and Its Analogues as Potent Histone Deacetylase Inhibitors
por: Li, Shang, et al.
Publicado: (2011)

The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
por: Tu, Huang-Ju, et al.
Publicado: (2018)

Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma
por: Tsai, I-Ting, et al.
Publicado: (2018)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Synthesis and Preclinical Evaluation of a Highly Improved Anticancer Prodrug Activated by Histone Deacetylases and Cathepsin L
por: Ueki, Nobuhide, et al.
Publicado: (2016)

A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo
por: Wu, Yi-Wen, et al.
Publicado: (2021)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells
por: Chao, Min-Wu, et al.
Publicado: (2017)

Bureau no. 23-R-009
por: Jacob, U
Publicado: (1978)

Histone deacetylases and their role in motor neuron degeneration
por: Lazo-Gómez, Rafael, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ev8f56vdfmbkstrebotshgh7hc